NO20006086D0 - Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein - Google Patents

Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein

Info

Publication number
NO20006086D0
NO20006086D0 NO20006086A NO20006086A NO20006086D0 NO 20006086 D0 NO20006086 D0 NO 20006086D0 NO 20006086 A NO20006086 A NO 20006086A NO 20006086 A NO20006086 A NO 20006086A NO 20006086 D0 NO20006086 D0 NO 20006086D0
Authority
NO
Norway
Prior art keywords
homocysteine
procedure
reactive protein
reducing levels
levels
Prior art date
Application number
NO20006086A
Other languages
English (en)
Other versions
NO20006086L (no
Inventor
Pamela Wang Anderson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20006086L publication Critical patent/NO20006086L/no
Publication of NO20006086D0 publication Critical patent/NO20006086D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20006086A 1998-06-17 2000-11-30 Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein NO20006086D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8960198P 1998-06-17 1998-06-17
PCT/US1999/012604 WO1999065306A1 (en) 1998-06-17 1999-06-04 Methods for reducing levels of homocysteine and c-reactive protein

Publications (2)

Publication Number Publication Date
NO20006086L NO20006086L (no) 2000-11-30
NO20006086D0 true NO20006086D0 (no) 2000-11-30

Family

ID=22218549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006086A NO20006086D0 (no) 1998-06-17 2000-11-30 Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein

Country Status (18)

Country Link
US (1) US6353003B1 (no)
EP (1) EP0966965A1 (no)
JP (1) JP2002518296A (no)
KR (1) KR20010052947A (no)
CN (1) CN1305342A (no)
AU (1) AU753035B2 (no)
BR (1) BR9911224A (no)
CA (1) CA2333384A1 (no)
EA (1) EA200100049A1 (no)
HR (1) HRP20000860A2 (no)
HU (1) HUP0102383A3 (no)
IL (1) IL138915A0 (no)
NO (1) NO20006086D0 (no)
PL (1) PL344841A1 (no)
SK (1) SK18802000A3 (no)
TR (1) TR200003713T2 (no)
WO (1) WO1999065306A1 (no)
ZA (1) ZA200005884B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585507A2 (en) * 2003-01-06 2005-10-19 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
WO2004093882A1 (ja) * 2003-04-18 2004-11-04 Advanced Medicine Research Institute 眼に適用する疾患治療剤
US20070003600A1 (en) * 2003-06-11 2007-01-04 Carolyn Moore Methods for reducing c-reactive protein
TWI386204B (zh) * 2008-04-10 2013-02-21 Mitsubishi Tanabe Pharma Corp 高半胱胺酸合成酶抑制劑

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
CZ286365B6 (cs) 1993-12-21 2000-03-15 Eli Lilly And Company Farmaceutický prostředek pro inhibici LDL oxidace a atherosklerosy
US5476862A (en) 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
JP4111352B2 (ja) 1996-05-21 2008-07-02 新日鐵住金ステンレス株式会社 ステンレス鋼の高清浄化精錬法
US6069175A (en) 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6025373A (en) 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
US6103740A (en) 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts

Also Published As

Publication number Publication date
TR200003713T2 (tr) 2001-04-20
HRP20000860A2 (en) 2001-10-31
HUP0102383A3 (en) 2003-01-28
EP0966965A1 (en) 1999-12-29
CN1305342A (zh) 2001-07-25
ZA200005884B (en) 2001-10-22
WO1999065306A1 (en) 1999-12-23
PL344841A1 (en) 2001-11-19
KR20010052947A (ko) 2001-06-25
JP2002518296A (ja) 2002-06-25
IL138915A0 (en) 2001-11-25
NO20006086L (no) 2000-11-30
AU753035B2 (en) 2002-10-03
CA2333384A1 (en) 1999-12-23
EA200100049A1 (ru) 2001-06-25
HUP0102383A2 (hu) 2002-01-28
SK18802000A3 (sk) 2001-09-11
AU4819299A (en) 2000-01-05
US6353003B1 (en) 2002-03-05
BR9911224A (pt) 2001-02-20

Similar Documents

Publication Publication Date Title
DE69932575D1 (de) Sprachkodierer und sprachdekodierer
NO972125L (no) Hemorroideblandinger og fremgangsmåte for anvendelse
NO993217L (no) Broenntetningssammensetninger og fremgangsmåter
NO980890D0 (no) Kontroll av trafikk og transport
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
NO991150D0 (no) Pyrazolopyrimidiner og pyrazolotriaziner
DE69836432D1 (de) Bildcoder und -decoder
NO20003096L (no) Sammensetninger og fremgangsmÕter for behandling av ADD
DK1041879T4 (da) Desinfektionsmiddel og fremstillingsmetode
NO991432L (no) Heterosykliske tioestere og ketoner
DK0954588T3 (da) OB fusionsprotein-sammensætninger og fremgangsmåder
NO20022334L (no) Ny sammensetning og anvendelse
NO975759D0 (no) Inokuleringsmiddel og fremgangsmåte for fremstilling av inokuleringsmiddel
NO20003427D0 (no) Lomasse og fremgangsmÕte for dens fremstilling
NO20012937L (no) Direkte spröytestöpt lukking og fremgangsmåte for denne
NO983240D0 (no) Fremgangsmate for analyse av korrosjon, og for forhindring av korrosjon
DK0804078T3 (da) Sammensætning og anvendelse deraf
NO981282D0 (no) Calcitriolderivater og deres anvendelser
NO20004355D0 (no) Retarderende systemer og anvendelse derav ved oljebrønnsementering
NO20012723D0 (no) Fremgangsmåte og system for prediktiv koding av datatabeller
DK1047445T3 (da) Modificerede enzymer og anvendelse heraf til peptidsyntese
NO20006086D0 (no) Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein
NO971448D0 (no) Anti-Fas rekombinante antistoffer og DNA derfor
DE69909361D1 (de) Süssmittelzusammensetzung und Verwendung
NO20012203L (no) Fremgangsmåte for å indeksere og bestemme den relative konsentrasjon av uttrykt mRNA

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application